The health care industry is experiencing innovative developments that can advance our society and produce vast growth potential.
On the upcoming webcast, As Genome-Editing Evolves, So Do The Investment Opportunities, Brett Winton, Director of Research at ARK Invest, and Manisha Samy, Analyst Genomic Revolution at ARK Invest, will highlight some of the initiatives in the health care segment, such as the developments in CRISPR genome-editing.
As a way to tap into the potential growth of the genomic revolution, ETF investors may consider something like the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG),
“Securities within ARKG are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business. One such way this is accomplished is by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation,” according to ARK.
Specifically, ARKG covers sub-sectors like Gene Therapy (21.3%), Targeted Therapeutics (17.7%), Beyond DNA (15.6%), Bioinformatics (13.7%), Instrumentation (13.5%), Molecular Diagnostics (8.9%), Next Generation Oncology (6.7%), Stem Cells (1.7%) and Agricultural Biology (<1%).